FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2230391954> ?p ?o ?g. }

• W2230391954 endingPage "1923" @default.
• W2230391954 startingPage "1917" @default.
• W2230391954 abstract "Objective To compare the efficacy and safety between tocilizumab added to methotrexate and tocilizumab switched from methotrexate in patients with active rheumatoid arthritis (RA). Methods This is a 2-year randomised, controlled study. RA patients with moderate or high disease activity despite methotrexate were randomly assigned either to tocilizumab added to methotrexate (add-on) or tocilizumab switched from methotrexate (switch). The primary endpoint was the DAS28 remission rate at week 24. Secondary objectives included other clinical efficacy indices, radiological outcomes assessed with the van der Heijde-modified total Sharp scoring system (mTSS), and safety. Results Of 223 randomised patients, 83% completed 52 weeks. DAS28 remission rates at week 24 were 70% for add-on and 55% for switch (p=0.02), but they became comparable at week 52 (72% vs 70%, p=0.86). Structural remission rates (mTSS≤0.5) at week 52 were not different (66% vs 64%, p=0.92). However, clinically relevant radiographic progression rates (CRRP; mTSS≥3) tended to be higher with the switch than with the add-on (15% vs 7%, p=0.07). Radiographic progression in the CRRP patients was larger with the switch than with the add-on (9.0/year vs 5.0/year, p=0.04). The difference in the mean C-reactive protein of the CRRP patients was significant for the first 24 weeks (1.56 vs 0.49, p=0.001) but not for the following 28 weeks (0.10 vs 0.04, p=0.1). Overall safety was preferable in the switch group. Conclusions In RA patients with inadequate response to methotrexate, tocilizumab added to methotrexate more rapidly suppressed inflammation than tocilizumab switched from methotrexate, leading to superior clinical efficacy and prevention of joint destruction. Trial registration number NCT01120366." @default.
• W2230391954 created "2016-06-24" @default.
• W2230391954 creator A5015953107 @default.
• W2230391954 creator A5016636355 @default.
• W2230391954 creator A5017958083 @default.
• W2230391954 creator A5039165431 @default.
• W2230391954 creator A5039490239 @default.
• W2230391954 creator A5049062202 @default.
• W2230391954 creator A5063192431 @default.
• W2230391954 creator A5072688345 @default.
• W2230391954 creator A5074411927 @default.
• W2230391954 creator A5075284186 @default.
• W2230391954 creator A5079071350 @default.
• W2230391954 creator A5083044716 @default.
• W2230391954 creator A5083314956 @default.
• W2230391954 creator A5087307078 @default.
• W2230391954 creator A5089112324 @default.
• W2230391954 creator A5091064461 @default.
• W2230391954 date "2016-01-05" @default.
• W2230391954 modified "2023-10-18" @default.
• W2230391954 title "Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)" @default.
• W2230391954 cites W1962992676 @default.
• W2230391954 cites W1996389186 @default.
• W2230391954 cites W2008873550 @default.
• W2230391954 cites W2018118744 @default.
• W2230391954 cites W2069473482 @default.
• W2230391954 cites W2080382012 @default.
• W2230391954 cites W2092154266 @default.
• W2230391954 cites W2096862304 @default.
• W2230391954 cites W2097874407 @default.
• W2230391954 cites W2116843833 @default.
• W2230391954 cites W2120393706 @default.
• W2230391954 cites W2125212735 @default.
• W2230391954 cites W2130010378 @default.
• W2230391954 cites W2142399236 @default.
• W2230391954 cites W2151858167 @default.
• W2230391954 cites W2155109530 @default.
• W2230391954 cites W2159269317 @default.
• W2230391954 cites W2165044662 @default.
• W2230391954 cites W2169537705 @default.
• W2230391954 cites W4210768724 @default.
• W2230391954 cites W4253469911 @default.
• W2230391954 cites W4254780119 @default.
• W2230391954 doi "https://doi.org/10.1136/annrheumdis-2015-208426" @default.
• W2230391954 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5099201" @default.
• W2230391954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26733110" @default.
• W2230391954 hasPublicationYear "2016" @default.
• W2230391954 type Work @default.
• W2230391954 sameAs 2230391954 @default.
• W2230391954 citedByCount "76" @default.
• W2230391954 countsByYear W22303919542016 @default.
• W2230391954 countsByYear W22303919542017 @default.
• W2230391954 countsByYear W22303919542018 @default.
• W2230391954 countsByYear W22303919542019 @default.
• W2230391954 countsByYear W22303919542020 @default.
• W2230391954 countsByYear W22303919542021 @default.
• W2230391954 countsByYear W22303919542022 @default.
• W2230391954 countsByYear W22303919542023 @default.
• W2230391954 crossrefType "journal-article" @default.
• W2230391954 hasAuthorship W2230391954A5015953107 @default.
• W2230391954 hasAuthorship W2230391954A5016636355 @default.
• W2230391954 hasAuthorship W2230391954A5017958083 @default.
• W2230391954 hasAuthorship W2230391954A5039165431 @default.
• W2230391954 hasAuthorship W2230391954A5039490239 @default.
• W2230391954 hasAuthorship W2230391954A5049062202 @default.
• W2230391954 hasAuthorship W2230391954A5063192431 @default.
• W2230391954 hasAuthorship W2230391954A5072688345 @default.
• W2230391954 hasAuthorship W2230391954A5074411927 @default.
• W2230391954 hasAuthorship W2230391954A5075284186 @default.
• W2230391954 hasAuthorship W2230391954A5079071350 @default.
• W2230391954 hasAuthorship W2230391954A5083044716 @default.
• W2230391954 hasAuthorship W2230391954A5083314956 @default.
• W2230391954 hasAuthorship W2230391954A5087307078 @default.
• W2230391954 hasAuthorship W2230391954A5089112324 @default.
• W2230391954 hasAuthorship W2230391954A5091064461 @default.
• W2230391954 hasBestOaLocation W22303919541 @default.
• W2230391954 hasConcept C126322002 @default.
• W2230391954 hasConcept C141071460 @default.
• W2230391954 hasConcept C168563851 @default.
• W2230391954 hasConcept C203092338 @default.
• W2230391954 hasConcept C2777178219 @default.
• W2230391954 hasConcept C2777575956 @default.
• W2230391954 hasConcept C2781059491 @default.
• W2230391954 hasConcept C71924100 @default.
• W2230391954 hasConcept C90924648 @default.
• W2230391954 hasConceptScore W2230391954C126322002 @default.
• W2230391954 hasConceptScore W2230391954C141071460 @default.
• W2230391954 hasConceptScore W2230391954C168563851 @default.
• W2230391954 hasConceptScore W2230391954C203092338 @default.
• W2230391954 hasConceptScore W2230391954C2777178219 @default.
• W2230391954 hasConceptScore W2230391954C2777575956 @default.
• W2230391954 hasConceptScore W2230391954C2781059491 @default.
• W2230391954 hasConceptScore W2230391954C71924100 @default.
• W2230391954 hasConceptScore W2230391954C90924648 @default.
• W2230391954 hasIssue "11" @default.
• W2230391954 hasLocation W22303919541 @default.
• W2230391954 hasLocation W22303919542 @default.
• W2230391954 hasLocation W22303919543 @default.

• next